NexImmune is a clinical-stage biotech developing a nanoparticle-based immune therapy platform called AIM (Artificial Immune Modulation) to treat cancer, autoimmune diseases, and infectious diseases. The AIM platform works by engineering nanoparticles that mimic dendritic cells — the immune system's instruction-giving cells — to direct specific T cells to either attack (in cancer or infection) or suppress (in autoimmune disease). The platform produces two product types: AIM ACT, which expands patient or donor T cells outside the body before infusing them back, and AIM INJ, an injectable off-the-shelf nanoparticle that works directly in the patient. NexImmune is prioritizing AIM INJ because it avoids the costly, patient-specific manufacturing required by CAR-T and similar therapies. The most advanced programs are NEXI-001 (acute myeloid leukemia) and NEXI-002 (multiple myeloma), both AIM ACT therapies in Phase I/II trials, though enrollment in both is paused due to resource constraints. NexImmune is pre-revenue with no approved products, funded entirely through capital raises, and operates with only six full-time employees. The core technology was originally licensed from Johns Hopkins. If products are eventually approved, NexImmune plans to commercialize through a focused U.S. sales force targeting oncologists and hematologists, with third-party distributors internationally. The company is also pursuing academic and institutional partnerships to advance autoimmune and infectious disease programs without fully funding development internally.